What's Happening?
Charles River Laboratories has joined the EASYGEN Consortium, an EU-backed initiative to develop a fully automated platform for manufacturing CAR-T cell therapies within 24 hours. The consortium aims to make these therapies more affordable and accessible across Europe. Charles River will leverage its expertise in 3D screening technologies to expedite early screening for safety and efficacy, contributing to the streamlined workflow for CAR-T therapy production.
Why It's Important?
The development of a rapid, in-hospital CAR-T cell manufacturing platform could revolutionize cancer treatment by increasing access to personalized therapies. Currently, CAR-T therapies are limited by time-intensive production processes, restricting their availability to patients. The EASYGEN Consortium's efforts to automate and expedite manufacturing could reduce costs and broaden access, particularly in non-academic clinical environments. This initiative aligns with the EU's goals to enhance healthcare delivery and support innovative treatments.
